
    
      To investigate as primary objective:

        -  Superiority to placebo and non-inferiority to LAS106521 measured by histological
           clearance of one predefined target lesion;

      To investigate as secondary objective:

        -  Superiority to LAS106521

        -  Improvement of treated lesions (lesion response)

        -  Assessment of tolerability and safety by physicians global assessment score (PGA, PGT)

        -  Patient's assessment of tolerability and efficacy and patient's compliance
    
  